Biological E Reveals Results of Phase II/III Trials on JE Vaccine

by Kathy Jones on  September 19, 2011 at 6:55 PM Indian Health News
RSS Email Print This Page Comment
Font : A-A+

Hyderabad based Biological E Limited has revealed that it has completed the Phase II and III trials of its inactivated Japanese Encephalitis (JE) vaccine on healthy kids aged between 1 to 3 years of age.
 Biological E Reveals Results of Phase II/III Trials on JE Vaccine
Biological E Reveals Results of Phase II/III Trials on JE Vaccine

The trials were conducted in eight different sites across the country and the company revealed that it will be submitted the results of the study to the Indian regulatory authority for licensure.

Commenting on the results of these trials, Dr. Vijay Kumar Datla, Chairman and Managing Director of Biological E. Limited said, "We are excited about the successful completion of our phase-II/III clinical study which enables us to offer this novel and safe vaccine to combat Japanese Encephalitis not only in India but also across Asia."

JE is one of the most common viral encephalitis that occurs in this part of the world. It is estimated that there are around 50,000 cases in Asia on an annual basis with resulting mortality rates ranging from 0.3% to 60%.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Vaccination for Children 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive